Table 3.

Molecular alterations in small duct iCC.

	Molecular Alteration	Frequency (%)	Reference
Authorized targeting drug available	FGFR2 translocation	15–18	Komuta et al. [120]
	IDH1/2	10–15	Javle et al. [115]
	BRAF V600E	3–6	Hyman et al. [121]
	ERBB2	2–3	Oh and Bang et al. [122]
	MSI-H	1–2	Le et al. [123]
	NTRK1-3	<1	Kam et al. [119]
	NRG1	<1	Kam et al. [119]
Authorized targeting drug not available	TP53 mutation	20–30	Thornblade et al. [124]
	RAS mutation	10–20	Thornblade et al. [124]
	ARID1A	5–15	Bezrookove et al. [125]
	BAP1	5–15	Moshbeh et al. [126]